Your browser doesn't support javascript.
loading
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Herriott, Ashleigh; Tudhope, Susan J; Junge, Gesa; Rodrigues, Natalie; Patterson, Miranda J; Woodhouse, Laura; Lunec, John; Hunter, Jill E; Mulligan, Evan A; Cole, Michael; Allinson, Lisa M; Wallis, Jonathan P; Marshall, Scott; Wang, Evelyn; Curtin, Nicola J; Willmore, Elaine.
Affiliation
  • Herriott A; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Tudhope SJ; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Junge G; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Rodrigues N; Laboratory of Lymphocyte Signaling and Oncoproteome, University Hospital of Cologne, Cologne, Germany.
  • Patterson MJ; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Woodhouse L; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Lunec J; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Hunter JE; Institute of Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Mulligan EA; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Cole M; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Allinson LM; Institute of Medical and Biological Engineering, University of Leeds, Leeds, UK.
  • Wallis JP; Department of Haematology, Freeman Hospital, Newcastle upon Tyne, UK.
  • Marshall S; Department of Haematology, City Hospitals Sunderland NHS Trust, Sunderland, UK.
  • Wang E; Biomarin Pharmaceutical Inc., Novato, California, USA.
  • Curtin NJ; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
  • Willmore E; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
Oncotarget ; 6(41): 43978-91, 2015 Dec 22.
Article in En | MEDLINE | ID: mdl-26539646
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Leukemia, Lymphocytic, Chronic, B-Cell / Poly(ADP-ribose) Polymerases / Poly(ADP-ribose) Polymerase Inhibitors / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Oncotarget Year: 2015 Document type: Article Affiliation country: United kingdom Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Leukemia, Lymphocytic, Chronic, B-Cell / Poly(ADP-ribose) Polymerases / Poly(ADP-ribose) Polymerase Inhibitors / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Oncotarget Year: 2015 Document type: Article Affiliation country: United kingdom Country of publication: United States